The wild west of sales forecasting in pharmaceuticals: When expectation meets reality

Are you on a quest for growth in the pharmaceutical industry?  Discover how accurate due diligence assessments and forecasting are critical to drive business growth.

Facing the challenges: Pipelines of many pharma companies are looking increasingly thin and need to be replenished in the coming years. Additionally, pharma companies also face significant challenges as patent exclusivity for around 200 drugs are set to expire by 2030. This incurs major financial losses by impacting up to 79 percent of company revenues. As a result, companies are shifting their focus toward inorganic growth strategies, like licensing agreements, to sustain growth amidst diminishing R&D development. However, substantial deviations in sales forecasts undermine their utility as a tool for decision-making.

Our analysis of 50 US prescription drugs reveals significant disparities between forecasted and actual sales figures during the initial five years post-…